Latest Cyclin-dependent kinase Stories
A serendipitous combination of technology and scientific discovery, coupled with a hunch, allowed University of Pittsburgh Cancer Institute researchers to reveal a previously invisible biological
A drug that blocks the action of the enzyme Cdk5 could substantially reduce brain damage if administered shortly after a stroke.
Robust antitumor activity of G1's novel CDK4/6 inhibitors to be highlighted in poster on April 7 CHAPEL HILL, N.C., March 27, 2014 /PRNewswire/ -- G1 Therapeutics, Inc., a privately
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently.
Blocking certain enzymes in the cell may prevent cancer cell division and growth.
Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells.
Study uncovers several compounds that inhibit cancer cell invasion, but also reveals that cancer drug paclitaxel does the oppositeâ€”it promotes cancer metastasis.
Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.
SAN DIEGO, Sept. 9 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. today announced the initiation of a phase I clinical trial of TG02, a unique oral multi-kinase inhibitor, in patients with advanced/refractory hematologic malignancies.
- A hairdresser.